A Brief History of Bio-Techne Corporation (TECH)

Bio-Techne Corporation, originally founded as Research and Diagnostic Systems, Inc. (R&D Systems), has evolved into a global leader in life sciences and diagnostics. The company was established in 1976 by Dr. Charles Kummeth, who has been instrumental in guiding its growth and diversification.

In its early years, the company focused on producing diagnostic assays and antibodies for clinical and research use. One of the key turning points was the development of its renowned T-Cell assays and cytokine detection kits, which established the company as a key player in immunology research.

Over the decades, Bio-Techne has significantly expanded its repertoire through strategic acquisitions and organic growth. Here are some important milestones in the company’s history:

• 2002: Acquired R&D Systems Europe, solidifying its presence in the European market.
• 2010: Launched its Proteome Profiler Arrays, a tool that revolutionized protein expression profiling.
• 2011: Acquired Tocris Bioscience, a leading supplier of reagents for non-clinical life science research, broadening its product portfolio.
• 2014: Rebranded as Bio-Techne Corporation to better reflect the broader range of technologies and markets it serves.
• 2016: Acquired Advanced Cell Diagnostics (ACD), expanding into the field of RNA in situ hybridization (ISH) assays.
• 2018: Entered the gene therapy sector through the acquisition of Exosome Diagnostics, a pioneer in liquid biopsy diagnostics.
• 2020: Played a critical role in the global response to the COVID-19 pandemic by providing essential reagents and diagnostic tools.

Today, Bio-Techne Corporation continues to be at the forefront of innovation in the life sciences industry, with a commitment to advancing research, diagnostics, and therapeutic development globally.

Who Owns Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH) is a publicly traded company, meaning ownership is distributed among the shareholders who own its stocks. As of recent data, several key stakeholders stand out in terms of ownership and influence over the company's operations. Highlighted below are some of the most significant shareholders:

• Institutional Investors: A large portion of Bio-Techne's ownership lies with institutional investors, such as mutual funds, pension funds, and insurance companies. These entities invest on behalf of individuals and organizations, often holding significant shares.
• Vanguard Group Inc.: One of the most prominent institutional investors in Bio-Techne. Vanguard Group is known for its large-scale investments across multiple industries and acts as a significant shareholder.
• BlackRock Inc.: Another major institutional investor, BlackRock Inc. holds a substantial amount of shares in Bio-Techne. BlackRock is one of the world’s largest asset management firms.
• State Street Corporation: State Street is also a significant shareholder, known for its extensive investments in many publicly traded companies, including Bio-Techne.
• Company Executives and Board Members: Executives and members of the Board of Directors often hold shares in Bio-Techne. Their ownership is not just a form of compensation but also aligns their interests with those of shareholders.
• Retail Investors: Individual investors who purchase stocks through brokerage accounts also own a portion of Bio-Techne. Although retail investors may not hold as many shares as institutional investors, they collectively contribute to the company’s ownership structure.

It’s important to note that the distribution of ownership can change due to trading activities, new stock issuance, and other corporate actions. Regular filings with the U.S. Securities and Exchange Commission (SEC) provide updates on the current ownership landscape.

Bio-Techne Corporation (TECH) Mission Statement

Bio-Techne Corporation, a global life sciences company, is dedicated to enhancing the quality of life through advancements in health sciences and technology. Our mission is to empower researchers and healthcare professionals with the tools and knowledge they need to drive innovation and discovery.

Bio-Techne's core mission elements include:

• Innovation: We strive to be at the forefront of scientific discovery by developing cutting-edge technologies and products that support groundbreaking research and clinical applications.
• Quality: Our commitment to excellence ensures that we provide reliable, high-quality products and services that researchers and clinicians can depend on.
• Collaboration: We believe in fostering partnerships with academic institutions, research organizations, and healthcare providers to accelerate the pace of scientific progress and medical breakthroughs.
• Customer Focus: Understanding and meeting the evolving needs of our customers is central to our mission. We are dedicated to providing exceptional support and service to facilitate their success.
• Integrity: We uphold the highest standards of ethics and integrity in all aspects of our business operations, ensuring trust and credibility with our stakeholders.
• Sustainability: We are committed to sustainable practices that minimize our environmental impact and contribute to the well-being of our global community.

Through our unwavering dedication to these principles, Bio-Techne aims to be a trusted partner in the scientific and medical communities, advancing knowledge and improving lives around the world.

How Bio-Techne Corporation (TECH) Works

Bio-Techne Corporation (TECH) is a globally recognized entity in the field of biotechnology, dedicated to providing innovative tools for research and clinical diagnostics. The company plays a crucial role in advancing scientific discovery through the development, manufacturing, and distribution of high-quality reagents, instruments, and services.

Core Areas of Operation

• Reagents and Consumables: Bio-Techne offers a vast array of reagents including proteins, antibodies, and small molecules. These products are essential for various types of biological research and clinical diagnostics.
• Instruments: The company manufactures cutting-edge instruments designed to enhance laboratory efficiency and improve research outcomes. These include automated systems for immunoassays, multiplex assays, and protein analysis.
• Diagnostics: Bio-Techne provides diagnostic solutions that support clinical laboratories in disease identification and monitoring. These solutions are integral to both routine clinical testing and specialized research.

Innovation and Research

• Research and Development: Bio-Techne invests significantly in R&D to continually enhance the performance and applicability of their products. This enables them to stay at the forefront of scientific advancements.
• Collaborations: The company collaborates with academic institutions, pharmaceutical companies, and biotech firms to foster innovation and expand the utility of its product offerings.
• Intellectual Property: Bio-Techne holds numerous patents, underscoring its commitment to technological innovation and the protection of proprietary technologies.

Quality and Compliance

• Quality Assurance: Bio-Techne maintains rigorous quality control processes to ensure that all products meet the highest standards of performance and reliability.
• Regulatory Compliance: The company adheres to strict regulatory guidelines from agencies such as the FDA and EMA, ensuring that their products are safe and effective for their intended use.
• Customer Support: Comprehensive customer support services, including technical support and troubleshooting, are provided to help customers maximize the utility of Bio-Techne's products.

Global Reach

• International Presence: Bio-Techne operates in multiple countries, with a wide network of distribution channels that ensure the timely delivery of products worldwide.
• Localized Services: The company offers localized support and services, tailoring their approach to meet the unique needs of different regional markets.
• Strategic Acquisitions: Bio-Techne has expanded its capabilities and market reach through strategic acquisitions of complementary businesses.

Through these structured approaches, Bio-Techne Corporation continuously drives advancements in biotechnology, contributing significantly to scientific research and healthcare improvements globally.

How Bio-Techne Corporation (TECH) Makes Money

Bio-Techne Corporation (TECH) is a prominent player in the biotechnology and life sciences industry. The company generates revenue through a diversified range of products and services that cater to various segments of the biomedical research and clinical diagnostics markets. Below are some of the primary ways in which Bio-Techne Corporation makes money:

• Reagents and Assays: One of the core revenue streams for Bio-Techne is the sale of reagents and assay kits. These are essential tools used in biochemical research, clinical diagnostics, and drug development. The company offers a vast catalog of high-quality antibodies, recombinant proteins, enzymes, and other biochemical reagents.
• Instruments and Systems: Bio-Techne also manufactures and sells a variety of instruments and systems that facilitate scientific research and diagnostic processes. This includes advanced technologies for cell imaging, molecular diagnostics, and protein analysis.
• Clinical Diagnostics: The company's clinical diagnostics division offers products that are used in medical laboratories for the detection and monitoring of diseases. This includes a range of immunoassays, molecular assays, and other diagnostic tests that help in accurate disease diagnosis and patient care management.
• Contract Research and Laboratory Services: Bio-Techne provides contract research services and laboratory services, offering expertise in various fields such as cell biology, molecular biology, and biochemistry. These services are crucial for pharmaceutical companies and academic institutions that require specialized research capabilities.
• Licensing and Intellectual Property: Another revenue stream comes from licensing their proprietary technologies and intellectual property to other companies. This generates royalties and licensing fees, adding to the company's income.
• Collaborations and Partnerships: Through strategic collaborations and partnerships with other biotechnology and pharmaceutical companies, Bio-Techne enhances its product offerings and market reach. These alliances often result in joint development projects and co-marketing agreements, contributing to revenue growth.

By leveraging its extensive portfolio of products and services, Bio-Techne Corporation effectively taps into multiple revenue streams, ensuring a steady flow of income from different sectors within the biotechnology and life sciences industry.